Compare Oracle Corporation (ORCL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oracle Corporation vs Sanofi SA — how do they compare? Oracle Corporation trades at $126.21 (market cap $365.96B), while Sanofi SA trades at $44.12 (market cap $104.85B). The key difference: Oracle Corporation is far larger — about 3.5× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.53%). Which is the better fit depends on your goals.
| ORCL | SNY | |
|---|---|---|
Market Cap | $365.96B | $104.85B |
Sector | Technology | Health |
52-Week High | $328.33 | $52.34 |
52-Week Low | $121.37 | $41.33 |
Enterprise Value | $495.21B | $121.38B |
Dividend Yield | 1.57% | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oracle (ORCL) is trading at $121.37, down 4.04% today, reflecting recent market volatility. The stock shows strong fundamentals with consistent earnings beats (Q3 2025-Q1 2026) and robust profitability metrics including 65.82% gross margin and 58.56% ROE. Technical indicators are mixed with a bearish moving average signal but bullish RSI readings. Recent news highlights Oracle's AI infrastructure expansion and partnership with OpenAI, driving investor interest despite concerns about capital requirements.
Oracle presents a compelling investment case with strong analyst support (65% buy ratings) and a $253.30 consensus price target representing significant upside. Key opportunities include AI-driven growth and cloud expansion, while risks involve high debt levels ($92.6B total liabilities) and competitive pressures in enterprise software. The upcoming Q2 2026 earnings report on June 10 will be critical for validating the AI growth narrative.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
